Standout Papers

Management of toxicities from immunotherapy: ESMO Clinical Prac... 2012 2026 2016 2021 1.7k
  1. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2017)
    John B.A.G. Haanen, Franck Carbonnel et al. Annals of Oncology
  2. Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma (2015)
    Dirk Schadendorf, F. Stephen Hodi et al. Journal of Clinical Oncology
  3. Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group (2012)
    Keith T. Flaherty, Caroline Robert et al. Zurich Open Repository and Archive (University of Zurich)
  4. A decade of immune-checkpoint inhibitors in cancer therapy (2020)
    Caroline Robert Nature Communications
  5. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab (2017)
    Nathalie Chaput, Patricia Lepage et al. Annals of Oncology
  6. Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer (2005)
    Sandrine Faivre, Catherine Delbaldo et al. Journal of Clinical Oncology
  7. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006) (2017)
    Jacob Schachter, Antoni Ribas et al. The Lancet
  8. Removal of C.I. Basic Green 4 (Malachite Green) from aqueous solutions by adsorption using cyclodextrin-based adsorbent: Kinetic and equilibrium studies (2006)
    Grégorio Crini, Harmel N. Peindy et al. Separation and Purification Technology
  9. Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma (2017)
    Jeffrey S. Weber, F. Stephen Hodi et al. Journal of Clinical Oncology
  10. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination (2016)
    C. Boutros, Ahmad A. Tarhini et al. Nature Reviews Clinical Oncology
  11. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study (2019)
    Caroline Robert, Antoni Ribas et al. The Lancet Oncology
  12. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study (2019)
    Georgina V. Long, Reinhard Dummer et al. The Lancet Oncology
  13. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial (2018)
    Reinhard Dummer, Paolo A. Ascierto et al. The Lancet Oncology
  14. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001 (2019)
    Omid Hamid, Caroline Robert et al. Annals of Oncology
  15. Electrochemotherapy – An easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: Results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study (2006)
    M. Marty, Gregor Serša et al. European Journal of Cancer Supplements
  16. CTLA-4 and PD-1/PD-L1 Blockade: New Immunotherapeutic Modalities with Durable Clinical Benefit in Melanoma Patients (2013)
    Patrick A. Ott, F. Stephen Hodi et al. Clinical Cancer Research
  17. Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2022)
    John B.A.G. Haanen, Michel Obéid et al. Annals of Oncology
  18. Association of Vitiligo With Tumor Response in Patients With Metastatic Melanoma Treated With Pembrolizumab (2015)
    Camille Hua, Lise Boussemart et al. JAMA Dermatology
  19. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial (2017)
    Michael A. Davies, Philippe Saïag et al. The Lancet Oncology
  20. Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial (2020)
    Ralf Gutzmer, Daniil Stroyakovskiy et al. The Lancet
  21. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial (2018)
    Reinhard Dummer, Paolo A. Ascierto et al. The Lancet Oncology
  22. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors (2018)
    Eléonora De Martin, Jean‐Marie Michot et al. Journal of Hepatology
  23. Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody (2016)
    Neil H. Segal, Theodore F. Logan et al. Clinical Cancer Research
  24. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma (2013)
    Jedd D. Wolchok, F. Stephen Hodi et al. Annals of the New York Academy of Sciences
  25. Tumour burden and efficacy of immune-checkpoint inhibitors (2021)
    Filippo Gustavo Dall’Olio, Aurélien Marabelle et al. Nature Reviews Clinical Oncology
  26. Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy (2022)
    Lucas Blanchard, Elisabeth Bellard et al. Cancer Cell
  27. The multiple roles of LDH in cancer (2022)
    Giuseppina Claps, Sara Faouzi et al. Nature Reviews Clinical Oncology

Immediate Impact

18 by Nobel laureates 18 from Science/Nature 146 standout
Sub-graph 1 of 18

Citing Papers

A systems view of the vascular endothelium in health and disease
2024 Standout
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
47 intermediate papers

Works of Caroline Robert being referenced

Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001
2019 Standout
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
2015 Standout
and 37 more

Author Peers

Author Last Decade Papers Cites
Caroline Robert 27403 15106 11183 640 40.6k
Michael B. Atkins 24830 15717 11813 570 39.8k
Alexander M.M. Eggermont 18119 9231 6568 386 25.1k
Jedd D. Wolchok 44357 15851 29224 558 63.2k
Daniel D. Von Hoff 23213 19391 2791 816 43.9k
Richard Pazdur 19104 10270 3564 582 36.2k
Howard A. Burris 25010 12786 3254 737 37.4k
Martin Gore 14140 12791 3567 377 29.0k
Michael T. Lotze 16922 20053 25546 495 56.3k
Frances R. Balkwill 22155 13853 18138 291 46.0k
Herbert M. Pinedo 15681 11909 3725 569 29.4k

All Works

Loading papers...

Rankless by CCL
2026